ALKBH5-mediated m6A demethylation of TXNDC5 drives malignant progression in gastric cancer
Epigenomics · 02.01.2026 · 18 (1) · 15-26
DOI: 10.1080/17501911.2025.2586450 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epigenomics, online erschienen am 11.11.2025. Verfasst von Wenkun Peng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: AlkB Homolog 5, RNA Demethylase, Stomach Neoplasms, Adenosine. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of China, Shandong Provincial Natural Science Foundation.
Abstract (Originalsprache)
BACKGROUND: Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide. N6-methyladenosine (m6A) modification plays a critical role in post-transcriptional gene regulation. This study aimed to elucidate the molecular mechanism by which the RNA demethylase ALKBH5 regulates GC progression through m6A modification of thioredoxin domain-containing protein 5 (TXNDC5). METHODS: Differential expression models of ALKBH5 and TXNDC5 were established in GC cells using RNA interference and gene overexpression. Methylated RNA immunoprecipitation (MeRIP-qPCR), qPCR, and Western blot were performed to assess ALKBH5-mediated m6A modification and its effect on TXNDC5 expression. Functional assays, including proliferation, migration, and invasion, as well as a xenograft mouse model, were used to evaluate their roles in GC progression. RESULTS: ALKBH5 was significantly upregulated in GC tissues and cells. Overexpression of ALKBH5 stabilized TXNDC5 expression in an m6A-dependent manner, thereby promoting malignant phenotypes. Conversely, ALKBH5 knockdown increased m6A methylation of TXNDC5, reduced TXNDC5 protein expression, and suppressed GC cell proliferation, migration, and invasion. In vivo experiments confirmed that loss of ALKBH5 impaired tumor growth. CONCLUSIONS: Our findings demonstrate that the ALKBH5-TXNDC5 axis drives GC progression through m6A-dependent regulation, highlighting ALKBH5 as a potential therapeutic target for GC. Stomach cancer is a serious disease that is often hard to treat. In this study, we focused on a protein called ALKBH5, which helps cancer cells grow. We found that ALKBH5 increases the level of another protein, TXNDC5, making stomach cancer cells stronger and more likely to spread. When ALKBH5 was blocked, TXNDC5 decreased, and the cancer cells became weaker. These results show that ALKBH5 May drive stomach cancer growth and could be a new target for treatment in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
- Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China.
Förderung
- Natural Science Foundation of China
- Shandong Provincial Natural Science Foundation
Zitieren
APA
Peng, W., Wei, X., Zhou, F., & Xu, H. (2026). ALKBH5-mediated m6A demethylation of TXNDC5 drives malignant progression in gastric cancer. Epigenomics, 18(1), 15-26. https://doi.org/10.1080/17501911.2025.2586450
Vancouver
Peng W, Wei X, Zhou F, Xu H. ALKBH5-mediated m6A demethylation of TXNDC5 drives malignant progression in gastric cancer. Epigenomics. 2026;18(1):15-26. doi:10.1080/17501911.2025.2586450
BibTeX
@article{Peng2026,
author = {Peng, Wenkun and Wei, Xiaoquan and Zhou, Feifei and Xu, Hongwei},
title = {ALKBH5-mediated m6A demethylation of TXNDC5 drives malignant progression in gastric cancer},
journal = {Epigenomics},
year = {2026},
volume = {18},
number = {1},
pages = {15--26},
doi = {10.1080/17501911.2025.2586450}
}
EUVIMED